Cargando…
Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment
Background: The impact of the COVID-19 pandemic on the mental health of patients suffering from addictive disorders is of major concern. This study aimed to explore the presence and potential increase in post-traumatic stress disorder (PTSD) symptoms, depression, and anxiety since the beginning of t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514667/ https://www.ncbi.nlm.nih.gov/pubmed/34658964 http://dx.doi.org/10.3389/fpsyt.2021.729460 |
_version_ | 1784583442850119680 |
---|---|
author | Fuchs-Leitner, Isabella Yazdi, Kurosch Gerstgrasser, Nikolas W. Tholen, Matthias G. Graffius, Sophie-Therés Schorb, Alexander Rosenleitner, Jan |
author_facet | Fuchs-Leitner, Isabella Yazdi, Kurosch Gerstgrasser, Nikolas W. Tholen, Matthias G. Graffius, Sophie-Therés Schorb, Alexander Rosenleitner, Jan |
author_sort | Fuchs-Leitner, Isabella |
collection | PubMed |
description | Background: The impact of the COVID-19 pandemic on the mental health of patients suffering from addictive disorders is of major concern. This study aimed to explore the presence and potential increase in post-traumatic stress disorder (PTSD) symptoms, depression, and anxiety since the beginning of the pandemic for patients in opioid substitution therapy (OST). Methods: This cross-sectional survey study evaluated a clinical sample of patients in OST (N = 123). Symptoms of post-traumatic stress disorder (PTSD) due to the COVID-19 pandemic were assessed by an adapted version of the impact of event scale (IES-R), resulting in two subgroups of low and high risk for PTSD. The depression, anxiety, and stress scale (DASS-21) was applied to collect data on the respective symptoms, and changes since the onset of the pandemic were reported on separate scales. Sociodemographic and COVID-19 related factors, as well as data on craving, consumption patterns, concomitant use, and the drug market were further assessed. Results: A binary logistic regression analysis confirmed the impact of self-perceived higher burden by psychological and economic factors on the elevated risk for PTSD due to the pandemic. The high-risk PTSD group also showed higher levels of depression, anxiety and stress, as well as a more pronounced deterioration in these symptoms since the pandemic. While reported levels of craving did not differ between the two groups, the high-risk PTSD group indicated a significantly higher increase in craving since the crisis, when compared to the low-risk group. Discussion: Our findings demonstrate elevated levels of clinical symptoms among patients in OST, with more than a quarter of patients found at risk for PTSD due to the COVID-19 pandemic. Furthermore, about 30–50% of our patients reported concerning levels of depression, anxiety, or stress. Special attention should be drawn to these findings, and potential deterioration of the situation should be addressed by health care facilities. Particularly, psychological, and financial burden due to the crisis were identified as factors increasing the risk for PTSD. These factors can easily be evaluated during routine anamneses, and might be a valuable source of information, when special attention is needed. |
format | Online Article Text |
id | pubmed-8514667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85146672021-10-15 Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment Fuchs-Leitner, Isabella Yazdi, Kurosch Gerstgrasser, Nikolas W. Tholen, Matthias G. Graffius, Sophie-Therés Schorb, Alexander Rosenleitner, Jan Front Psychiatry Psychiatry Background: The impact of the COVID-19 pandemic on the mental health of patients suffering from addictive disorders is of major concern. This study aimed to explore the presence and potential increase in post-traumatic stress disorder (PTSD) symptoms, depression, and anxiety since the beginning of the pandemic for patients in opioid substitution therapy (OST). Methods: This cross-sectional survey study evaluated a clinical sample of patients in OST (N = 123). Symptoms of post-traumatic stress disorder (PTSD) due to the COVID-19 pandemic were assessed by an adapted version of the impact of event scale (IES-R), resulting in two subgroups of low and high risk for PTSD. The depression, anxiety, and stress scale (DASS-21) was applied to collect data on the respective symptoms, and changes since the onset of the pandemic were reported on separate scales. Sociodemographic and COVID-19 related factors, as well as data on craving, consumption patterns, concomitant use, and the drug market were further assessed. Results: A binary logistic regression analysis confirmed the impact of self-perceived higher burden by psychological and economic factors on the elevated risk for PTSD due to the pandemic. The high-risk PTSD group also showed higher levels of depression, anxiety and stress, as well as a more pronounced deterioration in these symptoms since the pandemic. While reported levels of craving did not differ between the two groups, the high-risk PTSD group indicated a significantly higher increase in craving since the crisis, when compared to the low-risk group. Discussion: Our findings demonstrate elevated levels of clinical symptoms among patients in OST, with more than a quarter of patients found at risk for PTSD due to the COVID-19 pandemic. Furthermore, about 30–50% of our patients reported concerning levels of depression, anxiety, or stress. Special attention should be drawn to these findings, and potential deterioration of the situation should be addressed by health care facilities. Particularly, psychological, and financial burden due to the crisis were identified as factors increasing the risk for PTSD. These factors can easily be evaluated during routine anamneses, and might be a valuable source of information, when special attention is needed. Frontiers Media S.A. 2021-09-30 /pmc/articles/PMC8514667/ /pubmed/34658964 http://dx.doi.org/10.3389/fpsyt.2021.729460 Text en Copyright © 2021 Fuchs-Leitner, Yazdi, Gerstgrasser, Tholen, Graffius, Schorb and Rosenleitner. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Fuchs-Leitner, Isabella Yazdi, Kurosch Gerstgrasser, Nikolas W. Tholen, Matthias G. Graffius, Sophie-Therés Schorb, Alexander Rosenleitner, Jan Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment |
title | Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment |
title_full | Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment |
title_fullStr | Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment |
title_full_unstemmed | Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment |
title_short | Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment |
title_sort | risk of ptsd due to the covid-19 pandemic among patients in opioid substitution treatment |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514667/ https://www.ncbi.nlm.nih.gov/pubmed/34658964 http://dx.doi.org/10.3389/fpsyt.2021.729460 |
work_keys_str_mv | AT fuchsleitnerisabella riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment AT yazdikurosch riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment AT gerstgrassernikolasw riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment AT tholenmatthiasg riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment AT graffiussophietheres riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment AT schorbalexander riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment AT rosenleitnerjan riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment |